Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007141200) NOVEL N-ARYL AND N-HETEROARYL SUBSTITUTED PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2007/141200 International Application No.: PCT/EP2007/055376
Publication Date: 13.12.2007 International Filing Date: 01.06.2007
IPC:
C07D 213/69 (2006.01) ,C07D 401/10 (2006.01) ,A61K 31/4412 (2006.01) ,A61P 3/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
213
Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02
having three double bonds between ring members or between ring members and non-ring members
04
having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62
Oxygen or sulfur atoms
69
Two or more oxygen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4412
having oxo groups directly attached to the heterocyclic ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
Applicants:
ALCÁZAR-VACA, Manuel, Jesús [ES/ES]; ES (UsOnly)
ANDRÉS-GIL, José, Ignacio [ES/ES]; ES (UsOnly)
DAUTZENBERG, Frank, Matthias [DE/BE]; BE (UsOnly)
MACRITCHIE, Jacqueline [GB/GB]; GB (UsOnly)
OYARZABAL SANTAMARINA, Julen [ES/ES]; ES (UsOnly)
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE (AllExceptUS)
Inventors:
ALCÁZAR-VACA, Manuel, Jesús; ES
ANDRÉS-GIL, José, Ignacio; ES
DAUTZENBERG, Frank, Matthias; BE
MACRITCHIE, Jacqueline; GB
OYARZABAL SANTAMARINA, Julen; ES
Common
Representative:
JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30 B-2340 Beerse, BE
Priority Data:
06114917.502.06.2006EP
06123263.331.10.2006EP
Title (EN) NOVEL N-ARYL AND N-HETEROARYL SUBSTITUTED PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES
(FR) NOUVEAUX DÉRIVÉS DE PYRIDINONE SUBSTITUÉE PAR N-ARYLE ET N-HÉTÉROARYLE EN VUE D'UNE UTILISATION DANS DES MALADIES À MÉDIATION PAR MCH-1
Abstract:
(EN) The present invention concerns N-aryl and N-heteroaryl substituted pyridinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.
(FR) La présente invention concerne des dérivés de pyridinone substituée par N-aryle et N-hétéroaryle présentant une activité antagoniste de l'hormone de mélano-concentration (MCH), en particulier l'activité de MCH-1, représentés par la formule générale (I), un sel d'addition acide ou d'addition basique pharmaceutiquement acceptable desdits dérivés, une forme N-oxyde de ceux-ci ou un sel d'ammonium quaternaire de ceux-ci, les variables étant définies dans la revendication 1. Elle concerne en outre leur préparation, des compositions les comprenant et leur utilisation comme médicament. Les composés selon l'invention sont utiles pour la prévention et/ou le traitement de troubles psychiatriques, comprenant, mais sans y être limités, l'anxiété, les troubles de l'alimentation, les troubles de l'humeur, tels que les troubles bipolaires et la dépression, les psychoses, telles que la schizophrénie, et les troubles du sommeil; l'obésité; le diabète; les troubles sexuels et les troubles neurologiques.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)